A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Stopped VIR-2482 1200 mg did not demonstrate efficacy versus placebo in the primary analysis of the primary endpoint

Conditions

• Influenza A

Interventions

• BIOLOGICAL: VIR-2482 (450 mg)
• BIOLOGICAL: VIR-2482 (1200 mg)
• BIOLOGICAL: Placebo

Sponsor

Vir Biotechnology, Inc.